480.50 0.65 (0.14%)

197.25% Gain from 52W Low

1.8M Volume

NSENov 24, 2020 03:31 PM



Glenmark Pharmaceuticals Ltd.    
24 Nov 2020, 07:10PM
480.50
0.14%
default
Glenmark Pharmaceuticals Ltd.    
23 Nov 2020, 12:00PM
480.50
0.14%
480.50
0.14%
GLENMARK PHARMACEUTICALS LTD. - 532296 - Intimation Under The Securities And Exchange Board Of India (Listing ...
BSE India
We wish to inform you that Glenmark Pharmaceuticals Limited ('Company') has issued a notice of optional redemption to the holders of U.S. $200 million 4.5% Senior Notes due 2021 ('Notice') listed on the Singapore Exchange Securities Trading Limited, in accordance with the terms of the Indenture dated as of August 1, 2016 (as amended, supplemented, waived or otherwise modified from time to time), between, among others, the Company and Citicorp International Limited, as trustee. Copy of the Notice is attached herewith. Capitalised or other terms used but not defined herein shall, unless the context otherwise requires, have the meanings as set out in the Notice. We request you to kindly take this intimation on record and to treat the same as compliance with the applicable provisions of the SEBI LODR.
480.50
0.14%
480.50
0.14%
Earnings Call for Q2FY21 of Glenmark Pharmaceuticals Ltd.
Conference Call with Glenmark Pharmaceuticals Ltd. Management and Analysts on Q2FY21 Performance and Outlook. Listen to the full earnings transcript.
480.50
0.14%
GLENMARK PHARMACEUTICALS LTD. - 532296 - Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter ...
BSE India
Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2020. The said meeting of the Board commenced at 5.00 p.m. and concluded at 8.45 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarkpharma.com.
480.50
0.14%
480.50
0.14%
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Cessation
BSE India
Pursuant to Regulation 30 read with Schedule III Part A Para A (7) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have to inform you that Mr. Milind Sarwate (DIN: 00109854) was appointed as Non Executive Independent Director of the Company for a term of Five Years commencing from October 29, 2015 to October 28, 2020. Mr. Milind Sarwate, has conveyed that due to his pre-occupation, he would be unable to continue as Director on the Board of the Company post completion of his term as Non-Executive Independent Director with effect from close of business hours on October 28, 2020. Hence, Mr. Milind Sarwate ceases to be a Director of the Company from close of business hours on October 28, 2020.
480.50
0.14%
480.50
0.14%
GLENMARK PHARMACEUTICALS LTD. - 532296 - Closure of Trading Window
BSE India
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, November 6, 2020, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2020. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from September 30, 2020 to November 8, 2020 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2020.
default
  • Prabhudas Lilladhar increased Sell price target of Glenmark Pharmaceuticals Ltd. to 424.0 on 10 Nov, 2020.
  • Stock Price (481.7) crossed below 30 Day SMA (487.6) on 09 November, 2020
  • Stock Price (497.7) crossed above 50 Day SMA (483.58) on 04 November, 2020
  • Month Change by -20.4% (Crossed threshold 20%) on 22 July, 2020
  • Day volume (89266592.0) was 1004% of the Month Average Volume (8886245.0) on 22 June, 2020
More triggered alerts
Ex-Date Dividend Amount Dividend Type Record Date
Sept. 17, 20202.50FINAL-
Sept. 19, 20192.00FINAL-
Sept. 19, 20182.00FINAL-
Sept. 20, 20172.00FINAL-
Aug. 3, 20162.00FINAL-
All dividends by GLENMARK
Ex-Date Dividend Bonus Ratio Record Date
March 4, 20051:1-
All bonuses by GLENMARK
Ex-Date Dividend Old FVNew FV Record Date
Sept. 10, 200721-
Oct. 23, 2003102Oct. 31, 2003
All splits by GLENMARK